Rib-X Pharmaceuticals, Inc., based in New Haven, CT, is a privately-held biopharmaceutical company focused on discovering and developing novel antibiotics for drug-resistant pathogens. Rib-X uses the structural data of the ribosome, which performs an essential role in the process of protein synthesis to design novel, proprietary classes of antibiotics that have a broad-spectrum of activity and are highly effective against antibiotic resistant microorganisms. Rib-X has successfully completed Phase 2 clinical trials for two novel antibiotics with MRSA activity for treatment of resistant infections in hospitals. Rib-X also has multiple preclinical programs using its technology platform, one of which it is developing in collaboration with Sanofi. The Company was founded in 2000 around a scientific breakthrough pioneered at Yale University, the three-dimensional structure of the bacterial ribosome, which earned one of its founders a Nobel Prize in 2009.
Warburg Pincus led Rib-X’s Series B financing in 2003, Series C financing in 2006 as well as a subsequent financings in 2008 though 2011 to fund the development of its novel antibiotic candidates.
Back to Previous Page